On July 29, 2026, The Lancet published the full Phase 3 results for deramiocel, an investigational cell therapy whose reparative effect is attributed largely to the exosomes its cells secrete. The trial met its primary endpoint, slowing upper limb functional decline by 54 percent versus placebo. For anyone following exosome science, the more important detail is not the number. It is that the number survived independent peer review at one of medicine’s most selective journals, three weeks before an FDA decision date.
Regenerative medicine generates a great deal of press-release science. A company announces topline results, the stock moves, and the underlying data stay unpublished for a year or more. That is why the July 29 publication matters: the HOPE-3 dataset, which we covered in June when the FDA resumed its review, has now been examined by outside experts with every incentive to find problems with it. Below is what was published, where the exosome connection lies, and what the result does and does not tell you about the exosome products available outside of clinical trials.
What The Lancet Published
The paper is titled “Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.” Its lead author is Craig McDonald, M.D., of UC Davis Health, national principal investigator for both the HOPE-2 and HOPE-3 trials. The headline findings, as reported by trial sponsor Capricor Therapeutics:
- Design: randomized, double-blind, placebo-controlled Phase 3 trial in 106 participants, analyzed under a prespecified Statistical Analysis Plan (version 3.0).
- Primary endpoint met: upper limb functional decline slowed by 54 percent versus placebo on the Performance of the Upper Limb 2.0 scale, p = 0.03.
- Cardiac signal: concurrent benefits across several cardiac measures, which the authors call biologically supportive of a consistent effect across skeletal and cardiac muscle.
- Population: the first Phase 3 trial to show significant functional benefit in a largely non-ambulatory Duchenne population.
- Regulatory status: the Biologics License Application remains under active FDA review with a PDUFA target action date of August 22, 2026.
Duchenne muscular dystrophy affects roughly 15,000 people in the United States, primarily boys, and is caused by the absence of functional dystrophin. Deterioration of heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in the disease. There is no cure and treatment options remain limited, which is the context in which slowing an otherwise relentless decline by half is considered meaningful.
Where The Exosomes Come In
Deramiocel (CAP-1002) is not an exosome product. It is a cell product: allogeneic cardiosphere-derived cells, a rare population of cardiac cells given by infusion. The distinction matters, because consumer coverage frequently calls it “an exosome therapy,” which is not accurate.
The exosome connection is mechanistic. Per the sponsor’s description, cardiosphere-derived cells act by secreting extracellular vesicles known as exosomes, which target macrophages and shift their expression profile toward a healing rather than pro-inflammatory phenotype. The infused cells are understood to work less by replacing damaged tissue and more by releasing signaling packages that instruct resident immune cells to behave differently. These cells have been studied in more than 250 peer-reviewed publications and given to over 250 human subjects.
That is why HOPE-3 is read closely by people who never think about muscular dystrophy. If a cell therapy’s benefit is largely attributable to its secretome, that strengthens the broader hypothesis that the signaling cargo, not the cell, does much of the work. That hypothesis is why cell-based and cell-free approaches are studied side by side.
Why Peer Review Changes The Weight Of A Result
Not all evidence carries equal weight, and a useful habit when researching any regenerative therapy is asking where a claim sits in the hierarchy.
| Type of evidence | What it establishes | Weight it deserves |
|---|---|---|
| Clinic testimonial or before-and-after photo | That one person reported feeling better | Essentially none for predicting your outcome |
| Cell or animal study | That a mechanism is biologically plausible | Useful for direction, not for dosing or outcomes |
| Small uncontrolled human series | That it was tolerated in a few patients | Hypothesis-generating; no placebo comparison |
| Sponsor press release of topline data | What the sponsor chose to disclose | Meaningful but incomplete and unchecked |
| Peer-reviewed randomized controlled trial | That an effect held up against placebo and scrutiny | The standard regulators act on |
The HOPE-3 result moved from the fourth row to the fifth on July 29. Peer review is not an audit and it replicates nothing, but it removes the most common failure mode in this field: a sponsor selecting a favorable analysis after the fact, described in language nobody outside the company has checked.
Note the detail about SAP 3.0. The analysis followed a prespecified statistical plan, meaning the primary endpoint and the method for testing it were locked before the data were unblinded. That discipline separates a real trial from a fishing expedition, and it is worth looking for in any regenerative medicine study you encounter.
What This Does Not Mean For Products Sold Today
There are still zero FDA-approved exosome products for any therapeutic use in the United States. That was true before July 29 and it remains true. Deramiocel itself is not approved; the FDA can approve, reject, or request more information on August 22. The agency’s consumer alert on regenerative medicine products remains active, and warning letters to clinics marketing unapproved stem cell and exosome products have continued, as we detailed in our review of 2026 enforcement activity.
The correct reading of HOPE-3 is narrow. A rigorously designed trial of a cell therapy, in one disease, produced a peer-reviewed positive result, and the proposed mechanism runs through exosomes. That is encouraging for the underlying science. It is not a clearance for anything sold in a clinic today, and a provider who cites it as if it were is telling you something about their standards rather than about the therapy.
What To Ask Instead
Because published trial evidence is not yet available for most elective regenerative applications, the practical questions shift to the product and the people handling it. A serious supplier answers these without hesitation.
- Is the source material documented? Tissue source, donor screening, and processing method should be on paper, not described verbally.
- Is there a lot-specific certificate of analysis? A generic marketing sheet is not a COA. Our annotated COA example shows what the fields mean.
- What characterization was performed? Particle count, size distribution, sterility, endotoxin, and surface marker identity are the baseline. “Billions of exosomes” without a measurement method is not characterization.
- How is it stored and shipped? Cold chain integrity determines whether the vial resembles what left the lab.
These are the same standards a regulated product has to meet, which is why they are worth applying now. You can read how we approach them on our quality standards page and in our overview of why practitioners choose OmniGenix.
Questions About Product Quality And Documentation?
OmniGenix supplies biologics to licensed practitioners with lot-specific documentation and full characterization data. Whether you are a clinician evaluating suppliers or a patient trying to understand what your provider uses, we are glad to walk through the paperwork.
Frequently Asked Questions
Is deramiocel an exosome therapy?
No. Deramiocel is a cell therapy made of allogeneic cardiosphere-derived cells given by infusion. Its proposed mechanism runs through exosomes, meaning the infused cells are understood to work by secreting extracellular vesicles that reprogram macrophages toward a healing phenotype. The trial tested cells; the exosome involvement is mechanistic, not the product administered.
Does the HOPE-3 result mean exosome therapy is now FDA approved?
No. There are still zero FDA-approved exosome products for therapeutic use in the United States. Deramiocel itself is not approved either; its Biologics License Application is under FDA review with a target action date of August 22, 2026. A positive published trial is one input into that decision, not the decision itself.
What does a 54 percent slowing of decline actually mean?
It refers to the rate of functional loss, not to improvement. The measured outcome was performance of the upper limb on the PUL 2.0 scale, and treated participants lost function at roughly half the rate of the placebo group. Slowing progression is the realistic goal in a degenerative disease, and in this population it is considered clinically meaningful.
How should this affect my decision about a regenerative treatment?
Directly, very little. HOPE-3 studied one product in one rare genetic disease. It should modestly raise your confidence that the exosome signaling hypothesis has clinical substance, and it should not change your evaluation of any specific product offered to you. For that, focus on documentation, characterization data, lot-specific certificates of analysis, and the practitioner’s clinical judgment. Discuss any regenerative option with a qualified physician who knows your history.